Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
P-BCMA-ALLO1 in Relapsed/Refractory Multiple Myeloma
NCT04960579Phase 1Active, not recruiting
- Sponsor
- Poseida Therapeutics
- Start
- May 2022
- Primary completion
- Mar 2029
- Modality
- Gene Editing, Gene Silencing, CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label trial of P-BCMA-ALLO1 in multiple myeloma (MM) (18 arms), sponsored by Poseida Therapeutics. Primary endpoints: Maximum Tolerated Dose based on Dose Limiting Toxicities at 28 days, Safety and tolerability at 36 months and 1 more. Started May 2022; status: active, not recruiting.
02
Drugs
P-BCMA-ALLO1
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT04960579.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04960579.